Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02174861 · ClinicalTrials.gov registry record · Phase 2
A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.
A Phase 2 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 2
- Development phase
- 609
- Enrollment target
NCT02174861 is a Phase 2 study that has completed, run by Amgen. The registered enrollment target is 609 participants.
The verdict
NCT02174861, a Phase 2 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 609 participants
- Enrollment target
Study Summary
To assess the long-term safety and efficacy of erenumab.
Interventions
- DRUG Erenumab
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 609 participants |
| Start Date | 2014-06-30 |
| Est. Completion | 2017-05-26 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02174861
The ClinicalTrials.gov registry entry for NCT02174861 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 609 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Erenumab is the first listed.
NCT02174861 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02174861 about?
NCT02174861 is a clinical study titled "A Study to Assess the Long-term Safety and Efficacy of Erenumab (AMG 334) in Chronic Migraine Prevention.". To assess the long-term safety and efficacy of erenumab.
What is the current status of trial NCT02174861?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 609 participants. The study started on 2014-06-30. Estimated completion is 2017-05-26.
What interventions are being tested in trial NCT02174861?
The interventions under investigation include: Erenumab (DRUG).
Who is sponsoring clinical trial NCT02174861?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.